To investigate the correlation of KRAS gene mutation and surgery for clinical characteristics and prognosis in patients with colorectal cancer under a 5-year follow-up, clinical data of 277 patients with colorectal cancer treated from January 2010 to December 2010 were collected. Patients with KRAS gene mutation were detected by direct sequencing and followed up for 5 years. KRAS gene mutation effect on clinicopathological factors and univariate and multivariate survival were analyzed. Among 277 patients, 109 (39.8%) indicated KRAS gene exon 2 mutation, among which 12 colon mutations showed the highest frequency. Furthermore, KRAS gene mutation was revealed to have a correlation with the expression of EGFR, primary tumor site, and multiple metastases of tumor. In follow-up, the average survival time of patients carrying wild-type and mutant-type was 49.9 months and 50.7 months, respectively. Univariate analysis showed that high TNM stage, advanced age, pulmonary metastasis, hepatic metastasis, and multiple metastases were associated with poor postoperative prognosis in patients with colorectal cancer. Multivariate analysis showed that advanced age and high TNM stage were independent risk factors for postoperative outcome in patients with colorectal cancer. The median OS in IV patients after surgery still reached 39.6 months, and some patients survived. In conclusion, KRAS gene mutation in colorectal cancer patients is closely related to EGFR expression, primary tumor site and multiple metastasis, and the survival time of advanced patients is prolonged.
Keywords: KRAS gene; clinical feature; colorectal cancer; postoperative prognosis.
IJCEP Copyright © 2019.
Conflict of interest statement
KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic AnalysisMedical Advisory Secretariat. Ont Health Technol Assess Ser 10 (25), 1-49. PMID 23074403.KRAS status is predictive of outcomes in cetuximab and panitumumab monotherapy, and in cetuximab-irinotecan combination therapy. While KRAS testing is cost-effective for …
Relationships Among KRAS Mutation Status, Expression of RAS Pathway Signaling Molecules, and Clinicopathological Features and Prognosis of Patients With Colorectal CancerXB Wan et al. World J Gastroenterol 25 (7), 808-823. PMID 30809081.KRAS gene mutations do not affect downstream protein expression in CRC. KRAS protein is associated with poor tumor differentiation, older age, and a risk of tumor …
KRAS Mutation in Lung Metastases From Colorectal Cancer: Prognostic ImplicationsM Ghidini et al. Cancer Med 5 (2), 256-64. PMID 26715198.KRAS mutant colorectal cancer (CRC) patients develop lung and brain metastases more frequently than KRAS wild-type (WT) counterpart. We retrospectively investigated the p …
Clinical Significance and Prognostic Relevance of KRAS, BRAF, PI3K and TP53 Genetic Mutation Analysis for Resectable and Unresectable Colorectal Liver Metastases: A Systematic Review of the Current EvidenceDI Tsilimigras et al. Surg Oncol 27 (2), 280-288. PMID 29937183. - ReviewThe biological status of each tumor provides the basis for individualized cancer therapeutics. Data on the mutational status on CRLM should be a part of multidisciplinary …
Systematic Review: Anti-epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal CancerIJ Dahabreh et al. Ann Intern Med 154 (1), 37-49. PMID 21200037. - ReviewKRAS mutations are consistently associated with reduced overall and progression-free survival and increased treatment failure rates among patients with advanced colorecta …